The main objective of this study is to see whether the favorable preventative effect of
candesartan 16 mg per day in episodic migraine, that was found previously in two smaller
randomized controlled cross-over studies, can be confirmed in a larger, multicenter,
randomized controlled parallel group study. In addition it will be investigated whether 1)
also a smaller dose of 8 mg is effective, and 2) whether the favorable side effect profile,
seen in previous studies, can be confirmed, and whether it is even better with the smaller
dose.
Phase:
Phase 2
Details
Lead Sponsor:
Norwegian University of Science and Technology St. Olavs Hospital
Collaborators:
Haukeland University Hospital Molde Hospital Nordlandssykehuset HF Norwegian University of Science and Technology Rikshospitalet University Hospital Sorlandet Hospital HF St. Olavs Hospital Tartu University Hospital Ullevaal University Hospital University Hospital of North Norway University Hospital, Akershus